CN112094346B - 可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白cd142的单克隆抗体 - Google Patents
可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白cd142的单克隆抗体 Download PDFInfo
- Publication number
- CN112094346B CN112094346B CN202010484590.5A CN202010484590A CN112094346B CN 112094346 B CN112094346 B CN 112094346B CN 202010484590 A CN202010484590 A CN 202010484590A CN 112094346 B CN112094346 B CN 112094346B
- Authority
- CN
- China
- Prior art keywords
- antibody
- monoclonal antibody
- cell
- mouse anti
- transmembrane glycoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 11
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 title claims abstract description 10
- 108091007466 transmembrane glycoproteins Proteins 0.000 title claims abstract description 10
- 238000012163 sequencing technique Methods 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 abstract description 31
- 102000004169 proteins and genes Human genes 0.000 abstract description 19
- 108090000623 proteins and genes Proteins 0.000 abstract description 19
- 210000002966 serum Anatomy 0.000 abstract description 16
- 238000012216 screening Methods 0.000 abstract description 15
- 239000006228 supernatant Substances 0.000 abstract description 12
- 230000004927 fusion Effects 0.000 abstract description 11
- 238000001514 detection method Methods 0.000 abstract description 8
- 238000002649 immunization Methods 0.000 abstract description 8
- 230000003053 immunization Effects 0.000 abstract description 8
- 238000012795 verification Methods 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 3
- 238000002965 ELISA Methods 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 238000009739 binding Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000005880 cancer cell killing Effects 0.000 description 2
- 238000000749 co-immunoprecipitation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000007499 fusion processing Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 1
- KTXKIYXZQFWJKB-VZFHVOOUSA-N Ala-Thr-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O KTXKIYXZQFWJKB-VZFHVOOUSA-N 0.000 description 1
- DFCIPNHFKOQAME-FXQIFTODSA-N Arg-Ala-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O DFCIPNHFKOQAME-FXQIFTODSA-N 0.000 description 1
- FBLMOFHNVQBKRR-IHRRRGAJSA-N Arg-Asp-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FBLMOFHNVQBKRR-IHRRRGAJSA-N 0.000 description 1
- AUZAXCPWMDBWEE-HJGDQZAQSA-N Arg-Thr-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O AUZAXCPWMDBWEE-HJGDQZAQSA-N 0.000 description 1
- NTWOPSIUJBMNRI-KKUMJFAQSA-N Asn-Lys-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NTWOPSIUJBMNRI-KKUMJFAQSA-N 0.000 description 1
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 1
- UGKZHCBLMLSANF-CIUDSAMLSA-N Asp-Asn-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O UGKZHCBLMLSANF-CIUDSAMLSA-N 0.000 description 1
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OZHXXYOHPLLLMI-CIUDSAMLSA-N Cys-Lys-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OZHXXYOHPLLLMI-CIUDSAMLSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 108010055334 EphB2 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 1
- CRRFJBGUGNNOCS-PEFMBERDSA-N Gln-Asp-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CRRFJBGUGNNOCS-PEFMBERDSA-N 0.000 description 1
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 1
- IESFZVCAVACGPH-PEFMBERDSA-N Glu-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O IESFZVCAVACGPH-PEFMBERDSA-N 0.000 description 1
- HGJREIGJLUQBTJ-SZMVWBNQSA-N Glu-Trp-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O HGJREIGJLUQBTJ-SZMVWBNQSA-N 0.000 description 1
- VXEFAWJTFAUDJK-AVGNSLFASA-N Glu-Tyr-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O VXEFAWJTFAUDJK-AVGNSLFASA-N 0.000 description 1
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 1
- JSNNHGHYGYMVCK-XVKPBYJWSA-N Gly-Glu-Val Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O JSNNHGHYGYMVCK-XVKPBYJWSA-N 0.000 description 1
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 1
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 1
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 1
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 1
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101000938354 Homo sapiens Ephrin type-A receptor 1 Proteins 0.000 description 1
- WZPIKDWQVRTATP-SYWGBEHUSA-N Ile-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)=CNC2=C1 WZPIKDWQVRTATP-SYWGBEHUSA-N 0.000 description 1
- BOTVMTSMOUSDRW-GMOBBJLQSA-N Ile-Arg-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O BOTVMTSMOUSDRW-GMOBBJLQSA-N 0.000 description 1
- PWUMCBLVWPCKNO-MGHWNKPDSA-N Ile-Leu-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PWUMCBLVWPCKNO-MGHWNKPDSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 1
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 1
- KUEVMUXNILMJTK-JYJNAYRXSA-N Leu-Gln-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KUEVMUXNILMJTK-JYJNAYRXSA-N 0.000 description 1
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 1
- OGUUKPXUTHOIAV-SDDRHHMPSA-N Leu-Glu-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N OGUUKPXUTHOIAV-SDDRHHMPSA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 1
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
- RFQATBGBLDAKGI-VHSXEESVSA-N Lys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCCN)N)C(=O)O RFQATBGBLDAKGI-VHSXEESVSA-N 0.000 description 1
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 1
- MNGBICITWAPGAS-BPUTZDHNSA-N Met-Ser-Trp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O MNGBICITWAPGAS-BPUTZDHNSA-N 0.000 description 1
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 1
- 101100406879 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) par-2 gene Proteins 0.000 description 1
- 108010070503 PAR-2 Receptor Proteins 0.000 description 1
- JJHVFCUWLSKADD-ONGXEEELSA-N Phe-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O JJHVFCUWLSKADD-ONGXEEELSA-N 0.000 description 1
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 1
- XNQMZHLAYFWSGJ-HTUGSXCWSA-N Phe-Thr-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XNQMZHLAYFWSGJ-HTUGSXCWSA-N 0.000 description 1
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 1
- FEPSEIDIPBMIOS-QXEWZRGKSA-N Pro-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 FEPSEIDIPBMIOS-QXEWZRGKSA-N 0.000 description 1
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 1
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 1
- 102000018402 Protease-activated receptor 2 Human genes 0.000 description 1
- JPIDMRXXNMIVKY-VZFHVOOUSA-N Ser-Ala-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPIDMRXXNMIVKY-VZFHVOOUSA-N 0.000 description 1
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 1
- CDVFZMOFNJPUDD-ACZMJKKPSA-N Ser-Gln-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CDVFZMOFNJPUDD-ACZMJKKPSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- MQUZANJDFOQOBX-SRVKXCTJSA-N Ser-Phe-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O MQUZANJDFOQOBX-SRVKXCTJSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 1
- HOVLHEKTGVIKAP-WDCWCFNPSA-N Thr-Leu-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O HOVLHEKTGVIKAP-WDCWCFNPSA-N 0.000 description 1
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 1
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 1
- RIJPHPUJRLEOAK-JYJNAYRXSA-N Tyr-Gln-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O RIJPHPUJRLEOAK-JYJNAYRXSA-N 0.000 description 1
- WQOHKVRQDLNDIL-YJRXYDGGSA-N Tyr-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O WQOHKVRQDLNDIL-YJRXYDGGSA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- JIODCDXKCJRMEH-NHCYSSNCSA-N Val-Arg-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N JIODCDXKCJRMEH-NHCYSSNCSA-N 0.000 description 1
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 102000042287 type II cytokine receptor family Human genes 0.000 description 1
- 108091052254 type II cytokine receptor family Proteins 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Abstract
本发明涉及一种单克隆抗体,尤其为一种可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白CD142的单克隆抗体,包括其工艺包括如下步骤:S1,蛋白QC;S2,动物免疫;S3,血清检测和筛选;S4,融合及筛选;S5,亚克隆及筛选;S6,抗体上清制备;S7,抗体验证。本发明的可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白CD142的单克隆抗体具有高亲和力,高特异性,多应用场景等特点,并且可应用于活细胞富集。
Description
技术领域
本发明涉及一种单克隆抗体,尤其是一种可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白CD142的单克隆抗体。
背景技术
CD142是一种跨膜单链糖蛋白,与称为II型细胞因子受体的蛋白质家族有关。该受体家族的成员被细胞因子激活。细胞因子是可以影响白细胞行为的小蛋白。还发现VIIa与TF的结合开始细胞内的信号传导过程。TF/VIIa的信号传导功能在血管生成和细胞凋亡中发挥作用。促炎和促血管生成反应通过蛋白酶激活的受体2(PAR2)的TF/VIIa介导的裂解而激活。[8]Eph酪氨酸激酶受体(RTK)家族的EphB2和EphA2也可以被TF/VIIa裂解。CD142参与妊娠早期胎盘发育,与滋养细胞增殖分化及凋亡有关,目前市场上鲜有以CD142作为靶标载体的抗体类产品,并且都没有数据表明可以用于活肿瘤细胞富集。同时对于该研究领域缺乏有效的抗体工具。
发明内容
本发明的目的为提供一个靶向蛋白研究的工具,对不同癌症患者、癌症不同分期的蛋白表达变化及蛋白网络图谱的更深层次研究得以实现。
本发明采用的技术方案如下:一种可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白CD142的单克隆抗体,其工艺包括如下步骤:
S1,蛋白QC:采购商业化蛋白;
S2,动物免疫:选取6只Balb/c小鼠进行抗原免疫,并监测其血清效价以决定最优的免疫小鼠,初次免疫后会经过3到4次的加强,加强后将取小鼠血清检测滴度,筛选出滴度合格的小鼠冲击一次并用于融合,不合格的小鼠将继续一到两次加强至滴度最高后融合;
S3,血清检测和筛选:免疫小鼠眼眶取血,并用ELISA检测血清滴度,确定其血清效价合格;
S4,融合及筛选:取全脾和1/2的淋巴结,与骨髓瘤SP2/0细胞系融合,融合细胞铺到4块384孔板上,进行培养,收集所有孔的上清,用ELISA对免疫蛋白进行筛选,镜检有细胞的阳性孔转到96孔板继续培养,生长几天后,收集所有孔的上清,用ELISA检测与可溶片段检测原的反应,阳性孔进一步检测不同稀释度的蛋白结合,以进行亲和力排序,每个融合选免疫原亲和力最高的20个亲代克隆进入亚克隆;
S5,亚克隆及筛选:通过有限稀释法和ELISA筛选进行亚克隆,得到单克隆杂交瘤细胞,细胞铺96孔板,并培养至覆盖约1/6的底部,ELISA检测每个孔上清针对免疫抗原的反应,取OD值高且细胞状态良好的两个孔进入下轮亚克隆,重复上述步骤直到孔中细胞株阳性率100%,此时得到单克隆细胞株,经过最后一轮亚克隆后,所有阳性细胞立即扩大培养,一部分冻存供以后使用,另一部分进行上清或腹水制备;
S6,抗体上清制备:将最后获得的单克隆细胞株,通过腹部注射到F1小鼠用于抗体生产,产生的腹水用Protein A/G纯化,并用于后续检测;
S7,抗体验证:对获得的单克隆抗体细胞株进行ELISA,Western blotting,免疫共沉淀加质谱,抗体芯片等验证,确定最有效抗体。
作为本发明的一种优选技术方案:所述S2中Balb/c小鼠为8-12周龄的Balb/c小鼠。
作为本发明的一种优选技术方案:所述S3中血清效价合格线为血清效价大于10K。
作为本发明的一种优选技术方案:所述S4中的融合工艺为优化过的PEG融合。
作为本发明的一种优选技术方案:所述S4中4块384孔板上每孔细胞为102~104。
作为本发明的一种优选技术方案:所述S7中的ELISA验证具体为:取待检测的抗体包被96孔ELISA板,孵育,洗涤后脱脂牛奶过夜封闭,进行PBS洗涤后4℃保存待用;再进行抗原孵育,PBS洗涤,同时设置对照,加入His-HRP,TMB显色反应,酶标仪读数。
作为本发明的一种优选技术方案:所述S7中的抗体芯片具体为:使用芯片点样仪将抗-CD142抗体及对照抗体点制于以NC膜为基质的玻璃片,形成直径为100um的抗体点,将A375的全蛋白进行生物素标记,按2ug/ml的浓度孵育在抗体芯片上,室温孵育半小时,PBS轻柔清洗三遍,再用CY3-SA荧光二抗进行孵育,PBS清洗三遍,使用GenePix荧光芯片扫描仪523nm扫描芯片。
作为本发明的一种优选技术方案:所述的小鼠抗细胞表面糖蛋白CD142的单克隆抗体可变区测序结果为:
VHF1
EVKLVESGGGLVQPGGSLRLSCATS
VHCDR1
GFTFTEYH
VHF2
MSWVRQPPGKALEWLGF
VHCDR2
IRNRANGYTT
VHF3
EYSASVKGRFTISRDNSQNILYLQMNTLRTEDSATYYC
VHCDR3
ARLTMVVAEFDY
VHF4
WGQGTTLTVSS
VLF1
DIQMTQSPSSLSASLGGEVTITCKAS
VLCDR1
QDINKY
VLF2
IAWYQHKPGKGPRLLIH
VLCDR2
YTS
VLF3
TLQPGIPSRFSGSGSGRDYSFSVSNLEPEDIATYYC
VLCDR3
LQYDNLLT
VLF4
FGAGTKLELK。
本发明的可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白CD142的单克隆抗体具有高亲和力,高特异性,多应用场景等特点,并且可应用于活细胞富集。
附图说明
图1为本发明优选实施例中抗体流式细胞术结果图;
图2为本发明优选实施例中癌细胞杀伤结果图;
图3为本发明优选实施例中抗体芯片检测实验结果图。
具体实施方式
需要说明的是,在不冲突的情况下,本申请中的实施例及实施例中的特征可以相互组合,下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
参照图1,本发明优选实施例提供了一种可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白CD142的单克隆抗体,其工艺包括如下步骤:
S1,蛋白QC:采购商业化蛋白;具体的,在本实施例中采购的为义翘神州公司的货号:13133-H08H的蛋白。
S2,动物免疫:选取6只Balb/c小鼠进行抗原免疫,并监测其血清效价以决定最优的免疫小鼠,初次免疫后会经过3到4次的加强,加强后将取小鼠血清检测滴度,筛选出滴度合格的小鼠冲击一次并用于融合,不合格的小鼠将继续一到两次加强至滴度最高后融合;具体的,优化了的佐剂和免疫方法能产生针对大多数抗原的高亲和力的抗体(IgG亚型)。
S3,血清检测和筛选:免疫小鼠眼眶取血,并用ELISA检测血清滴度,确定其血清效价合格;
S4,融合及筛选:取全脾和1/2的淋巴结,与骨髓瘤SP2/0细胞系融合,融合细胞铺到4块384孔板上,进行培养,收集所有孔的上清,用ELISA对免疫蛋白进行筛选,镜检有细胞的阳性孔转到96孔板继续培养,生长几天后,收集所有孔的上清,用ELISA检测与可溶片段检测原的反应,阳性孔进一步检测不同稀释度的蛋白结合,以进行亲和力排序,每个融合选免疫原亲和力最高的20个亲代克隆进入亚克隆;
S5,亚克隆及筛选:通过有限稀释法和ELISA筛选进行亚克隆,得到单克隆杂交瘤细胞,细胞铺96孔板,并培养至覆盖约1/6的底部,ELISA检测每个孔上清针对免疫抗原的反应,取OD值高且细胞状态良好的两个孔进入下轮亚克隆,重复上述步骤直到孔中细胞株阳性率100%,此时得到单克隆细胞株,经过最后一轮亚克隆后,所有阳性细胞立即扩大培养,一部分冻存供以后使用,另一部分进行上清或腹水制备;
S6,抗体上清制备:将最后获得的单克隆细胞株,在本实施例中最终获得6株单克隆细胞株,通过腹部注射到F1小鼠用于抗体生产,产生的腹水用Protein A/G纯化,并用于后续检测;
S7,抗体验证:对获得的7株单克隆抗体细胞株进行ELISA,Western blotting,免疫共沉淀加质谱,抗体芯片等验证,确定最有效抗体。
本实施例中:所述S2中Balb/c小鼠为8-12周龄的Balb/c小鼠。
本实施例中:所述S3中血清效价合格线为血清效价大于10K。
本实施例中:所述S4中的融合工艺为优化过的PEG融合。
本实施例中:所述S4中4块384孔板上每孔细胞为102~104。
本实施例中:所述S7中的ELISA验证具体为:取待检测的抗体包被96孔ELISA板,孵育,洗涤后脱脂牛奶过夜封闭,PBS洗涤,4℃保存待用。抗原孵育(梯度稀释),PBS洗涤,同时设置对照。加入His-HRP(抗原带His标签),TMB显色反应,酶标仪读数。
在本实施例中,本发明人通过S7的ELISA亲和力验证得到6个细胞株的亲和力如下表:
nM | 100 | 50 | 25 | 12.5 | 6.25 | 3.125 | 1.57 | 0.78 | 0.4 | 0.2 | 0.1 | NC | 亲和力nM |
1G3 | 3.292 | 3.309 | 3.215 | 3.244 | 2.738 | 2.072 | 1.333 | 0.582 | 0.263 | 0.130 | 0.078 | 0.054 | 0.78 |
1M10 | 2.992 | 2.949 | 2.945 | 3.036 | 2.730 | 2.053 | 1.428 | 0.587 | 0.268 | 0.119 | 0.073 | 0.052 | 0.78 |
3C2 | 3.384 | 3.275 | 3.405 | 3.451 | 3.150 | 3.016 | 2.634 | 1.639 | 0.674 | 0.357 | 0.145 | 0.053 | 0.4 |
4M3 | 1.581 | 1.462 | 1.355 | 1.475 | 1.298 | 0.916 | 0.758 | 0.322 | 0.182 | 0.086 | 0.061 | 0.042 | 1.57 |
1C10 | 1.796 | 1.696 | 1.608 | 1.613 | 1.598 | 1.428 | 0.902 | 0.473 | 0.200 | 0.123 | 0.078 | 0.050 | 1.57 |
4H11 | 2.869 | 3.055 | 2.960 | 2.882 | 2.622 | 2.106 | 1.678 | 0.877 | 0.377 | 0.156 | 0.087 | 0.049 | 0.78 |
需要补充的是,在这个实施例中,我们还分别进行了抗体的流式细胞术验证和癌细胞杀伤实验。
具体如图1所示,MDA-MB-231细胞作为检测细胞系,使用PBS清洗,EDTA消化,转移至离心管中,离心弃上清后用PBS重悬,山羊血清常温封闭1小时,一抗孵育,工作浓度50ug/ml,荧光二抗孵育,工作浓度1:300。结果显示,本抗体可以应用流式细胞实验。
如图2所示,癌细胞杀伤实验为:在96孔板中配制100ul细胞MDA-MB-231悬液,预培养24小时,向培养板中加入10ul不同稀释梯度的抗-CD142抗体,加入偶联小分子药物的小鼠二抗,培养3天,向每孔加入10ul CCK-8溶液,孵育1-4小时,用酶标仪测定再450nm处的吸光度。实验结果显示该抗体对癌细胞MDA-MB-231很好的杀伤作用。
本实施例中:所述S7中的抗体芯片具体为:使用芯片点样仪将抗-CD142抗体及对照抗体点制于以NC膜为基质的玻璃片,形成直径为100um的抗体点,将A375的全蛋白进行生物素标记,按2ug/ml的浓度孵育在抗体芯片上,室温孵育半小时,PBS轻柔清洗三遍,再用CY3-SA荧光二抗进行孵育,PBS清洗三遍,使用GenePix荧光芯片扫描仪523nm扫描芯片。
实验结果如图3所示,实验结果显示抗-CD142(克隆1M10)对目标蛋白有明显富集结合效果,荧光强度较强而对照抗体没有发生抗原抗体结合反应。
本实施例中:所述的小鼠抗细胞表面糖蛋白CD142的单克隆抗体可变区测序结果为:
VHF1
EVKLVESGGGLVQPGGSLRLSCATS
VHCDR1
GFTFTEYH
VHF2
MSWVRQPPGKALEWLGF
VHCDR2
IRNRANGYTT
VHF3
EYSASVKGRFTISRDNSQNILYLQMNTLRTEDSATYYC
VHCDR3
ARLTMVVAEFDY
VHF4
WGQGTTLTVSS
VLF1
DIQMTQSPSSLSASLGGEVTITCKAS
VLCDR1
QDINKY
VLF2
IAWYQHKPGKGPRLLIH
VLCDR2
YTS
VLF3
TLQPGIPSRFSGSGSGRDYSFSVSNLEPEDIATYYC
VLCDR3
LQYDNLLT
VLF4
FGAGTKLELK。
对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。不应将权利要求中的任何附图标记视为限制所涉及的权利要求。
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
序列表
<110> 普众发现医药科技(上海)有限公司
<120> 可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白CD142的单克隆抗体
<141> 2023-10-10
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 25
<212> PRT
<213> Artificial Sequence
<400> 1
Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Thr Ser
20 25
<210> 2
<211> 8
<212> PRT
<213> Artificial Sequence
<400> 2
Gly Phe Thr Phe Thr Glu Tyr His
1 5
<210> 3
<211> 17
<212> PRT
<213> Artificial Sequence
<400> 3
Met Ser Trp Val Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Gly
1 5 10 15
Phe
<210> 4
<211> 10
<212> PRT
<213> Artificial Sequence
<400> 4
Ile Arg Asn Arg Ala Asn Gly Tyr Thr Thr
1 5 10
<210> 5
<211> 38
<212> PRT
<213> Artificial Sequence
<400> 5
Glu Tyr Ser Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
1 5 10 15
Ser Gln Asn Ile Leu Tyr Leu Gln Met Asn Thr Leu Arg Thr Glu Asp
20 25 30
Ser Ala Thr Tyr Tyr Cys
35
<210> 6
<211> 12
<212> PRT
<213> Artificial Sequence
<400> 6
Ala Arg Leu Thr Met Val Val Ala Glu Phe Asp Tyr
1 5 10
<210> 7
<211> 11
<212> PRT
<213> Artificial Sequence
<400> 7
Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
1 5 10
<210> 8
<211> 26
<212> PRT
<213> Artificial Sequence
<400> 8
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
1 5 10 15
Gly Glu Val Thr Ile Thr Cys Lys Ala Ser
20 25
<210> 9
<211> 6
<212> PRT
<213> Artificial Sequence
<400> 9
Gln Asp Ile Asn Lys Tyr
1 5
<210> 10
<211> 17
<212> PRT
<213> Artificial Sequence
<400> 10
Ile Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile
1 5 10 15
His
<210> 11
<211> 3
<212> PRT
<213> Artificial Sequence
<400> 11
Tyr Thr Ser
1
<210> 12
<211> 36
<212> PRT
<213> Artificial Sequence
<400> 12
Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
1 5 10 15
Arg Asp Tyr Ser Phe Ser Val Ser Asn Leu Glu Pro Glu Asp Ile Ala
20 25 30
Thr Tyr Tyr Cys
35
<210> 13
<211> 8
<212> PRT
<213> Artificial Sequence
<400> 13
Leu Gln Tyr Asp Asn Leu Leu Thr
1 5
<210> 14
<211> 10
<212> PRT
<213> Artificial Sequence
<400> 14
Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
1 5 10
Claims (1)
1.可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白CD142的单克隆抗体,其特征在于,可变区测序结果为:
VHF1
EVKLVESGGGLVQPGGSLRLSCATS
VHCDR1
GFTFTEYH
VHF2
MSWVRQPPGKALEWLGF
VHCDR2
IRNRANGYTT
VHF3
EYSASVKGRFTISRDNSQNILYLQMNTLRTEDSATYYC
VHCDR3
ARLTMVVAEFDY
VHF4
WGQGTTLTVSS
VLF1
DIQMTQSPSSLSASLGGEVTITCKAS
VLCDR1
QDINKY
VLF2
IAWYQHKPGKGPRLLIH
VLCDR2
YTS
VLF3
TLQPGIPSRFSGSGSGRDYSFSVSNLEPEDIATYYC
VLCDR3
LQYDNLLT
VLF4
FGAGTKLELK。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010484590.5A CN112094346B (zh) | 2020-06-01 | 2020-06-01 | 可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白cd142的单克隆抗体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010484590.5A CN112094346B (zh) | 2020-06-01 | 2020-06-01 | 可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白cd142的单克隆抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112094346A CN112094346A (zh) | 2020-12-18 |
CN112094346B true CN112094346B (zh) | 2024-01-05 |
Family
ID=73749662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010484590.5A Active CN112094346B (zh) | 2020-06-01 | 2020-06-01 | 可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白cd142的单克隆抗体 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112094346B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102393776B1 (ko) * | 2020-12-30 | 2022-05-04 | (주)이노베이션바이오 | Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체 |
WO2024083162A1 (en) * | 2022-10-19 | 2024-04-25 | Multitude Therapeutics Inc. | Antibodies, antibody-drug conjugates, preparations and uses thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101717447A (zh) * | 2009-12-17 | 2010-06-02 | 山西省生物研究所 | 一种抗人重组组织因子单克隆抗体的制备方法 |
WO2011065935A1 (en) * | 2009-11-24 | 2011-06-03 | Cornell University | Methods for monoclonal antibody production |
CN103880960A (zh) * | 2014-04-02 | 2014-06-25 | 福州迈新生物技术开发有限公司 | 一种分泌抗cd10分子的单克隆抗体及其应用 |
CN104388392A (zh) * | 2014-10-30 | 2015-03-04 | 苏州大学 | 一种恩诺沙星单克隆抗体及其制备方法和应用 |
CN105349495A (zh) * | 2015-11-17 | 2016-02-24 | 清华大学 | 抗凝血因子ix单克隆抗体的杂交瘤细胞株 |
CN105400769A (zh) * | 2015-11-17 | 2016-03-16 | 清华大学 | 抗凝血因子viii单克隆抗体的杂交瘤细胞株 |
CN107383199A (zh) * | 2017-03-15 | 2017-11-24 | 艾比玛特医药科技(上海)有限公司 | 一种s‑腺苷蛋氨酸合成酶的单克隆抗体及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018036117A1 (zh) * | 2016-08-22 | 2018-03-01 | 复旦大学 | 靶向于组织因子的抗体、其制备方法和用途 |
-
2020
- 2020-06-01 CN CN202010484590.5A patent/CN112094346B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011065935A1 (en) * | 2009-11-24 | 2011-06-03 | Cornell University | Methods for monoclonal antibody production |
CN101717447A (zh) * | 2009-12-17 | 2010-06-02 | 山西省生物研究所 | 一种抗人重组组织因子单克隆抗体的制备方法 |
CN103880960A (zh) * | 2014-04-02 | 2014-06-25 | 福州迈新生物技术开发有限公司 | 一种分泌抗cd10分子的单克隆抗体及其应用 |
CN104388392A (zh) * | 2014-10-30 | 2015-03-04 | 苏州大学 | 一种恩诺沙星单克隆抗体及其制备方法和应用 |
CN105349495A (zh) * | 2015-11-17 | 2016-02-24 | 清华大学 | 抗凝血因子ix单克隆抗体的杂交瘤细胞株 |
CN105400769A (zh) * | 2015-11-17 | 2016-03-16 | 清华大学 | 抗凝血因子viii单克隆抗体的杂交瘤细胞株 |
CN107383199A (zh) * | 2017-03-15 | 2017-11-24 | 艾比玛特医药科技(上海)有限公司 | 一种s‑腺苷蛋氨酸合成酶的单克隆抗体及其应用 |
Non-Patent Citations (3)
Title |
---|
An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors;Esther等;Cancer Research;第74卷(第04期);1214-1226 * |
人凝血因子Ⅶ单克隆抗体的制备与鉴定;吕茂民等;生物技术通讯;第19卷(第01期);73-75 * |
具有抗凝活性抗人组织因子单克隆抗体的制备与鉴定;陈尧等;细胞与分子免疫学杂志;第32卷(第04期);544-548 * |
Also Published As
Publication number | Publication date |
---|---|
CN112094346A (zh) | 2020-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210230269A1 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
CN110914304A (zh) | Cd96抗体、其抗原结合片段及医药用途 | |
CN113015749A (zh) | 靶向cd3的抗体、双特异性抗体及其用途 | |
CN113150151B (zh) | 一种C5aR抗体及其制备方法和应用 | |
CN112094346B (zh) | 可应用于肿瘤细胞捕获的小鼠抗细胞单链跨膜糖蛋白cd142的单克隆抗体 | |
CN106866820B (zh) | 一种用于捕获肿瘤细胞的抗人角蛋白18的单克隆抗体及其应用 | |
CN110590943B (zh) | 抗登革热病毒抗体及其应用 | |
CN116217716A (zh) | 一种识别柯萨奇病毒a2、a4和a5的单克隆抗体及其应用 | |
CN114213541B (zh) | 一种全能核酸酶的单克隆抗体及其制备方法 | |
CN116375867A (zh) | 抗gprc5d抗体及其应用 | |
CN112094345B (zh) | 可应用于肿瘤细胞捕获的小鼠抗免疫球蛋白关联βCD79b的单克隆抗体 | |
CN113004413B (zh) | 猪IgG3的单克隆抗体、该单克隆抗体特异性识别的抗原表位肽及其应用 | |
CN112094350B (zh) | 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体 | |
CN112279917B (zh) | 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd138的单克隆抗体 | |
TW202204406A (zh) | 抗個體遺傳型抗體及使用其之方法 | |
KR102021537B1 (ko) | 황열 바이러스 감염 진단용 신속진단키트 및 이를 이용한 황열 바이러스 검출방법 | |
WO2023109785A1 (zh) | 一种用于检测血清中sTNFR2的抗体及试剂盒 | |
CN117069840B (zh) | 特异性检测il-21的抗体及应用 | |
CN117683121B (zh) | 抗水痘-带状疱疹病毒抗体及其应用 | |
WO2022121899A1 (zh) | 一种特异性结合Strep-Tag II标签的抗体及其应用 | |
CN111349157B (zh) | 钙粘附蛋白6的单克隆抗体及其应用 | |
CN117209605B (zh) | 特异性结合il-15的抗体及其应用 | |
JP5448424B2 (ja) | ヒトIgGのFcを含有するタンパク質の測定試薬 | |
WO2024067151A1 (zh) | 抗呼吸道合胞病毒抗体及其相关应用 | |
CN110483641B (zh) | 干扰素诱导型gtp酶的单克隆抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |